| The key factor in the current scenario for | | | | developments in the market. |
| next-generation omics-based diagnostic technologies | | | | • Understanding of the various applications and |
| is the level of accuracy in the results, followed by the | | | | their importance in the development of new |
| capacity to detect early, and cost. Cost currently | | | | diagnostics products |
| remains a major constraint, as people and healthcare | | | | • Many novel tests such as mass spectrometry |
| institutes are skeptical of investing in technologies | | | | and microarrays are expected to make a significant |
| that have not provided very wide and acceptable | | | | difference in the prognosis, monitoring and diagnosis |
| results. The impact of cost constraints will diminish as | | | | of cancer patients.. |
| the cost/value benefit is established. The future | | | | Key Market Issues |
| market will demand reliability, which means | | | | • Past and current trends are still dominated by |
| reproducible results on standard equipment, and | | | | symptom based diagnosis. |
| techniques with less deviation across laboratories and | | | | • However, current healthcare objectives focus |
| methodologies. The importance of accuracy remains | | | | on early detection. |
| constant. Industry participants will continue to position | | | | • The future is about genetic study and disease |
| their diagnostic products based on accuracy levels. | | | | pre-disposition, which will test the probability of |
| Emphasis will also remain on its capacity to test the | | | | acquiring a disease or a disorder, enabling |
| probability of disease as early as possible through a | | | | precautionary steps. |
| non-invasive method of diagnosis. | | | | • Evolving technology development based on |
| The report discusses drivers, restraints, challenges | | | | omics technologies are making diagnostic tests less |
| and opportunities and market estimates of the global | | | | expensive. |
| diagnostics market in genomics, proteomics and | | | | • Accuracy remains the key demand for next |
| metabolomics on the basis of: | | | | generation omics based diagnostics. |
| • Technologies | | | | Key findings from this report |
| • Applications | | | | • Mass spectrometry is used to identify potential |
| • Strategic issues and innovations | | | | circulating protein biomarkers for non-small cell lung |
| Key features of this report | | | | cancer. |
| • Measures the global diagnostics market with | | | | • Omics and diagnostics have been helpful in the |
| respect to technologies and applications | | | | diagnosis of H1N1, but genome-based techniques |
| • Analyzes the market with respect to drivers, | | | | have proved vital in identifying the strain of the virus. |
| restraints, challenges, opportunities and market | | | | • Genome sequencing remains the most |
| estimates | | | | challenging task, as it requires a great deal of time |
| • Identifies trends and innovations in the markets | | | | and investment. |
| analyzed | | | | • Biomarkers in omics have contributed greatly to |
| • Analyzes and forecasts the revenues of regional | | | | the early diagnosis of cancer. |
| market segments | | | | Key questions answered |
| • In-depth analysis of competitive landscape, | | | | • What are the existing and pipeline technologies |
| top-selling products and services | | | | and products in the diagnostics market? |
| Scope of this report | | | | • What are the major application areas of |
| • Understanding the existing and emerging | | | | diagnostics? |
| applications of diagnostic in the three omics | | | | • What are the key market developments of the |
| technologies of proteomics, genomics and | | | | top companies profiled in this report? |
| metabolomics. | | | | • What are the trends and innovations in the |
| • Analyses of the products and technological | | | | global diagnostics market? |